Intra-arterial cisplatin

Phase 2Small molecule

SSouthern Illinois University

Intra-arterial cisplatin is one of 66 small molecule programs targeting Oropharynx Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharynx CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Oropharynx CancerPhase 1

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

281 competitors in Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

36 2

Erbitux

IImclone

Phase 3

26 3

Beyfortus

BeiGene

Phase 3

7 4

Imfinzi

AstraZeneca

Phase 3

5 5

Lenvima

Eisai

Phase 3

4 6

Ibrance

Pfizer

Phase 3

4 7

Taxotere

AAvyxa

Phase 3

16 8

Imjudo

AstraZeneca

Phase 3

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

6 10

Gilotrif

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oropharynx Cancer1 trial

Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer

Terminated·SSouthern Illinois University·Phase 1·NCT01587820·1 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

Completed·SSouthern Illinois University·Phase 2·NCT00304278·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intra-arterial cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intra-arterial cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intra-arterial cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southern Illinois University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSouthern Illinois University

Intra-arterial cisplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oropharynx Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News